Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid eye disease
Pharma
Argenx cans Vyvgart trials in thyroid eye disease over futility
Argenx is discontinuing its late-stage UplighTED studies of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease.
Fraiser Kansteiner
Dec 15, 2025 10:00am
Improved access helps Amgen's Tepezza to a sales increase
Aug 7, 2024 8:35am
Amgen lays out plan to boost sales of newly acquired Tepezza
Oct 31, 2023 11:29am
Horizon plays 'pass the glass' in World Sight Day campaign
Sep 15, 2022 8:25am
Horizon's eye disease awareness juggernaut continues apace
Jul 15, 2022 10:45am
'Dear TED': Horizon asks patients to write to their eye disease
May 12, 2022 11:50am
